Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: Emcure is effectively repositioning Poviztra as a mass‑market GLP‑1 for obesity in India, using a steep 55% entry‑dose cut (now ₹3,999/mon...
